InventisBio Co., Limited (SHA:688382)
22.67
+0.19 (0.85%)
At close: May 12, 2026
InventisBio Revenue
InventisBio had revenue of 42.54M CNY in the quarter ending March 31, 2026, with 419.51% growth. This brings the company's revenue in the last twelve months to 71.64M, down -57.45% year-over-year. In the year 2025, InventisBio had annual revenue of 37.29M, down -77.91%.
Revenue (ttm)
71.64M
Revenue Growth
-57.45%
P/S Ratio
181.47
Revenue / Employee
393.64K
Employees
168
Market Cap
13.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 37.29M | -131.50M | -77.91% |
| Dec 31, 2024 | 168.79M | -16.74M | -9.02% |
| Dec 31, 2023 | 185.53M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.87B |
| Pacific Shuanglin Bio-pharmacy | 2.60B |
| Anhui Anke Biotechnology (Group) | 2.56B |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Inner Mongolia Furui Medical Science | 1.63B |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |
| Chengdu Easton Biopharmaceuticals | 1.35B |
| Hualan Biological Vaccine | 1.20B |